Please ensure Javascript is enabled for purposes of website accessibility

Tag Archives: intrexon

Intrexon posts profit in quarter

Intrexon, of Germantown, a biotechnology company, posted a profit in the fourth quarter but an overall loss for the year. Intrexon reported net income for the quarter ended Dec. 31 of $18.8 million, or 18 cents per diluted share, compared ...

Read More »

Intrexon offers to buy Exemplar

Intrexon Corp., of Germantown, a synthetic biology company, Monday announced it has offered to acquire the remaining stake in Exemplar Genetics, a company that assists researchers in the study of life-threatening human diseases. Financial terms were not disclosed. Gregory Frost, ...

Read More »

Intrexon partners on cartilage products

Intrexon Corp., of Germantown, a synthetic biology company, announced it is collaborating with Histogenics Corp., a Waltham, Massachusetts-based regenerative medicine firm, to develop treatments to repair human cartilage. Histogenics will pay Intrexon $10 million as a technology access fee, with ...

Read More »

Intrexon posts loss in quarter

Intrexon, of Germantown, a synthetic biology company, reported a net loss of nearly $53 million for the second quarter. Intrexon’s loss was $52.9 million, or 53 cents per share, compared with a net loss of $6.5 million, or $2.45 per ...

Read More »

Intrexon closes deal with Trans Ova

Intrexon Corp., of Germantown, a synthetic biology company, announced it has completed the acquisition of Trans Ova Genetics L.C., an Iowa-based provider of bovine reproductive technologies.  Trans Ova will function as a wholly owned subsidiary of Intrexon. Trans Ova stockholders ...

Read More »

Germantown-based Intrexon agrees to acquire Medistem

Intrexon Corp., of Germantown, a developer of synthetic biological products targeting health, food, energy and environmental industries, said it has signed a definitive agreement to acquire San Diego-based Medistem Inc., a stem-cell company, in a cash-and-stock deal valued at approximately ...

Read More »